Narrative review / 2008
Curcumin is safe up to 12 g daily for 3 months in phase I trials and may have potential therapeutic roles across various chronic diseases.
This review summarizes research on curcumin, the active compound in turmeric. Preclinical studies suggest curcumin has antiproliferative, chemopreventive, and therapeutic potential across diverse conditions by modulating kinases, transcription factors, and cell cycle proteins. Pilot phase I clinical trials have shown curcumin to be safe even when consumed at a daily dose of 12 g for 3 months. Other clinical trials suggest a potential therapeutic role for curcumin in diseases including familial adenomatous polyposis, inflammatory bowel disease, ulcerative colitis, colon cancer, pancreatic cancer, hypercholesteremia, atherosclerosis, pancreatitis, psoriasis, chronic anterior uveitis, and arthritis.
- Study type
- Narrative review
- Who was studied
- Human clinical trial participants and preclinical models
- What was measured
- Curcumin safety, molecular mechanisms, and potential therapeutic roles
THE PAPER
Curcumin as "Curecumin": from kitchen to clinic.
Goel A, Kunnumakkara AB, Aggarwal BB. Biochem Pharmacol, 2008.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.